

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4432737

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	CHANGE OF ADDRESS OF ASSIGNEE
RESUBMIT DOCUMENT ID:	504371022

CONVEYING PARTY DATA

Name	Execution Date
MERRIMACK PHARMACEUTICALS, INC.	04/03/2017

RECEIVING PARTY DATA

Name:	IPSEN BIOPHARM LTD.
Street Address:	ASH ROAD, WREXHAM INDUSTRIAL ESTATE
City:	WREXHAM
State/Country:	GREAT BRITAIN
Postal Code:	LL13 9UF

PROPERTY NUMBERS Total: 92

Property Type	Number
Patent Number:	8147867
Patent Number:	8329213
Patent Number:	8658203
Patent Number:	8703181
Patent Number:	8992970
Patent Number:	9339497
Patent Number:	9364473
Patent Number:	9452162
Patent Number:	9492442
Application Number:	60567921
Application Number:	61659211
Application Number:	61784382
Application Number:	62089685
Application Number:	62147389
Application Number:	62207435
Application Number:	62207709
Application Number:	62207760
Application Number:	62208209
Application Number:	62216736

PATENT

Property Type	Number
Application Number:	62242796
Application Number:	62242835
Application Number:	62242873
Application Number:	62243935
Application Number:	62244061
Application Number:	62244082
Application Number:	62244926
Application Number:	62265409
Application Number:	62269511
Application Number:	62269756
Application Number:	62273244
Application Number:	62278751
Application Number:	62281458
Application Number:	62281473
Application Number:	62302341
Application Number:	62308924
Application Number:	62323245
Application Number:	62323422
Application Number:	62328830
Application Number:	62337961
Application Number:	62338324
Application Number:	62341223
Application Number:	62343313
Application Number:	62345178
Application Number:	62351193
Application Number:	62355640
Application Number:	62362735
Application Number:	62370449
Application Number:	62394870
Application Number:	62414050
Application Number:	62415821
Application Number:	62416317
Application Number:	62422807
Application Number:	62430470
Application Number:	62433687
Application Number:	62433925
Application Number:	14151632
Application Number:	14632422

Property Type	Number
Application Number:	14879302
Application Number:	14879358
Application Number:	14964239
Application Number:	14964571
Application Number:	14965140
Application Number:	14966458
Application Number:	14979666
Application Number:	15059640
Application Number:	15213127
Application Number:	15227561
Application Number:	15227631
Application Number:	15241106
Application Number:	15241128
Application Number:	15296536
Application Number:	15331318
Application Number:	15331393
Application Number:	15331648
Application Number:	15337274
Application Number:	15341377
Application Number:	15341619
Application Number:	15363761
Application Number:	15363923
Application Number:	15363978
Application Number:	15364021
Application Number:	15375039
Application Number:	15403441
PCT Number:	US2005015349
PCT Number:	US2013044961
PCT Number:	US2013045495
PCT Number:	US2015064491
PCT Number:	US2016027515
PCT Number:	US2016047727
PCT Number:	US2016047814
PCT Number:	US2016047827
PCT Number:	US2016057247

CORRESPONDENCE DATA

Fax Number: (734)418-4281

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (734) 418-4280
Email: lzerby@honigman.com
Correspondent Name: CYNTHIA M. BOTT, PH.D.
Address Line 1: HONIGMAN MILLER SCHWARTTZ AND COHN LLP
Address Line 2: 350 EAST MICHIGAN AVENUE, SUITE 300
Address Line 4: KALAMAZOO, MICHIGAN 49007

ATTORNEY DOCKET NUMBER:	263266-411103
NAME OF SUBMITTER:	CYNTHIA M. BOTT, PH.D.
SIGNATURE:	/Cindy M. Bott/
DATE SIGNED:	05/26/2017

Total Attachments: 18

source=Chg of Address#page1.tif
source=Chg of Address#page2.tif
source=Chg of Address#page3.tif
source=Chg of Address#page4.tif
source=Chg of Address#page5.tif
source=Chg of Address#page6.tif
source=Chg of Address#page7.tif
source=Chg of Address#page8.tif
source=Chg of Address#page9.tif
source=Chg of Address#page10.tif
source=Chg of Address#page11.tif
source=Chg of Address#page12.tif
source=Chg of Address#page13.tif
source=Chg of Address#page14.tif
source=Chg of Address#page15.tif
source=Chg of Address#page16.tif
source=Chg of Address#page17.tif
source=Chg of Address#page18.tif

Assignment Recordation Branch
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313

Re: Change of Address for Ipsen Biopharm Ltd.

Dear Sir/Madam,

This is a request to record a change of address for the Assignee Ipsen Biopharm Ltd.
from

190 Bath Road
Sough Berkshire, United Kingdom
SL1 3XE

to

Ash Road, Wrexham Industrial Estate
Wrexham, GB
LL13 9UF

Attached is a copy of the original Coversheet(s) and the Assignment document.

If there are any questions with regards to the request for change of address, questions and clarifications may be directed to the undersigned at the phone number or address listed below.

Dated: 5/26/17

Respectfully submitted,

By Cynthia M. Bott
Cynthia M. Bott, Ph.D.
Registration No.: 46,568
Telephone: (734) 418-4280

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4417716

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT	
NATURE OF CONVEYANCE:	Corrective Assignment to correct the ADDRESS OF THE ASSIGNEE previously recorded on Reel 042377 Frame 0696. Assignor(s) hereby confirms the ASSIGNMENT.	
CONVEYING PARTY DATA		
Name		Execution Date
MERRIMACK PHARMACEUTICALS, INC.		04/03/2017
RECEIVING PARTY DATA		
Name:	IPSEN BIOPHARM LTD.	
Street Address:	ASH ROAD, WREXHAM INDUSTRIAL ESTATE	
City:	WREXHAM	
State/Country:	GREAT BRITAIN	
Postal Code:	LL13 9UF	
PROPERTY NUMBERS Total: 92		
Property Type	Number	
Patent Number:	8147867	
Patent Number:	8329213	
Patent Number:	8658203	
Patent Number:	8703181	
Patent Number:	8992970	
Patent Number:	9339497	
Patent Number:	9364473	
Patent Number:	9452162	
Patent Number:	9492442	
Application Number:	60567921	
Application Number:	61659211	
Application Number:	61784382	
Application Number:	62089685	
Application Number:	62147389	
Application Number:	62207435	
Application Number:	62207709	
Application Number:	62207760	
Application Number:	62208209	
Application Number:	62216736	

PATENT

REEL: 042522 FRAME: 0339

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4392522

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
MERRIMACK PHARMACEUTICALS, INC.		04/03/2017
RECEIVING PARTY DATA		
Name:	IPSEN BIOPHARM LTD.	
Street Address:	190 BATH ROAD	
City:	SOUGH BERKSHIRE	
State/Country:	UNITED KINGDOM	
Postal Code:	SL1 3XE	
PROPERTY NUMBERS Total: 92		
Property Type	Number	
Patent Number:	8147867	
Patent Number:	8329213	
Patent Number:	8658203	
Patent Number:	8703181	
Patent Number:	8992970	
Patent Number:	9339497	
Patent Number:	9364473	
Patent Number:	9452162	
Patent Number:	9492442	
Application Number:	60567921	
Application Number:	61659211	
Application Number:	61784382	
Application Number:	62089685	
Application Number:	62147389	
Application Number:	62207435	
Application Number:	62207709	
Application Number:	62207760	
Application Number:	62208209	
Application Number:	62216736	
Application Number:	62242796	

PATENT ASSIGNMENT

This PATENT ASSIGNMENT (this "Assignment"), dated as of April 3, 2017 (the "Assignment Effective Date"), is entered into by and between Merrimack Pharmaceuticals, Inc., a Delaware corporation ("Assignor"), and Ipsen Biopharm Ltd., a company registered under the laws of England and Wales ("Assignee"), (each a "Party" and collectively, the "Parties"). Capitalized terms used herein but not defined in this Assignment shall have the meanings ascribed thereto in the Asset Purchase Agreement (as defined below).

WHEREAS, Assignor is the owner of the patents and patent applications identified on Schedule A hereto (the "Assigned Patents");

WHEREAS, Assignor and Assignee have entered into that certain Asset Purchase and Sale Agreement dated as of January 7, 2017 (the "Asset Purchase Agreement") and pursuant to such Asset Purchase Agreement shall enter into that certain Intellectual Property License Agreement (the "IP License Agreement"); and

WHEREAS, consistent with the transactions contemplated by the Asset Purchase Agreement, Assignee desires to acquire, and Assignor desires to transfer, the entire right, title and interest in and to the Assigned Patents.

NOW, THEREFORE, in accordance with the Asset Purchase Agreement and the IP License Agreement, and in consideration of the promises and of the mutual covenants and agreements contained herein and therein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor and Assignee hereby agree as follows:

1. Conveyance. As of the Assignment Effective Date, Assignor does hereby assign, transfer and convey to Assignee, and Assignee does hereby accept from Assignor, all of Assignor's right, title and interest in and to the Assigned Patents, including all remedies against infringements thereof, and all claims, causes of action, rights of recovery and rights of set-off of any kind, all damages and payments for past, present and future infringement or misappropriation of such Assigned Patents, and the right to sue and recover for past, present and future infringements or misappropriations of such Assigned Patents, and any and all corresponding rights that have been, now or hereafter may be secured throughout the world with respect to such Assigned Patents.

2. Recordation. Assignor hereby authorizes the Commissioner of Patents and Trademarks in the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign countries or multinational authorities, to record Assignee as the assignee of all of Assignor's right, title and interest in, to and under the Assigned Patents. Upon Assignee's request, Assignor undertakes and agrees to execute all formalities and such further assurances as may reasonably be required in order to permit Assignee (or its successors or assigns) to hold and enjoy the Assigned Patents assigned hereunder and to obtain the recordal of this assignment of the Assigned Patents. The Parties agree to reiterate their consent to this Assignment by confirmatory acts or contracts (i.e. Deed of Assignment) which might be

reasonably required after the Assignment Effective Date to complete the necessary formalities for its execution, particularly, the filing of the assignment of the Assigned Patents at the appropriate patent office.

3. No Conflict. The Parties acknowledge and agree that this Assignment shall be subject to and governed by the provisions of the Asset Purchase Agreement or the IP License Agreement. Nothing contained in this Assignment is intended to, shall or shall be deemed to modify, alter, amend, expand upon or otherwise change any of the rights, remedies or obligations of the Parties under the Asset Purchase Agreement or the IP License Agreement.

4. Amendment and Waivers. Subject to applicable Law and except as otherwise provided in this Assignment or the Asset Purchase Agreement, the Parties may mutually amend or waive any provision of this Assignment at any time. No amendment or waiver of any provision of this Agreement shall be valid unless the same shall be in writing and signed by each of the Parties. No waiver by either Party of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. No failure or delay by any Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof.

5. Successors and Assigns. This Assignment shall be binding upon and inure to the benefit of and be enforceable by each of the Parties named herein and its respective successors and permitted assigns.

6. Counterparts. This Assignment may be executed in two or more counterparts, each of which shall be deemed an original but both of which together shall constitute one and the same instrument. This Assignment may be executed and delivered by e-mail of a .pdf, .tif, .jpeg or similar attachment ("Electronic Delivery"), and any such counterparty delivered using Electronic Delivery shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

7. Construction. Headings set forth in this Assignment are for convenience of reference purposes only and shall not affect or be deemed to affect in any way the meaning or interpretation of this Assignment or any term or provision hereof. The language used in this Assignment shall be deemed to be the language chosen by the Parties hereto to express their mutual intent, and no rule of strict construction shall be applied against either Party. The Parties agree that they have been represented by counsel during the negotiation and execution of this Assignment and, therefore, waive the application of any Law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the Party drafting such agreement or document.

8. Severability. Any term or provision of this Assignment that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of

competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the Parties agree that the body making the determination of invalidity or unenforceability shall have the power to reduce the scope, duration or area of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Assignment shall be enforceable as so modified after the expiration of the time within which the judgment may be appealed.


9. Governing Law; Jurisdiction. This Assignment shall be governed by, and construed in accordance with, the Laws of the State of Delaware, without giving effect to conflicts of laws principles that would result in the application of the Law of any other state. Each of the Parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the Court of Chancery of the State of Delaware, or, if such court finds it lacks subject matter jurisdiction, the federal court of the United States of America sitting in Delaware, and any appellate court from any thereof, in any suit, action, legal proceeding or claim arising out of or relating to this Assignment or the transactions contemplated hereby or for recognition or enforcement of any judgment relating thereto, and each of the Parties hereby irrevocably and unconditionally (i) agrees not to commence any such suit, action, legal proceeding or claim except in the Court of Chancery of the State of Delaware, or, if such court finds it lacks subject matter jurisdiction, the federal court of the United States of America sitting in Delaware, and any appellate court from any thereof, (ii) agrees that any claim in respect of any such suit, action, legal proceeding or claim may be heard and determined in the Court of Chancery of the State of Delaware, or, if such court finds it lacks subject matter jurisdiction, the federal court of the United States of America sitting in Delaware, and any appellate court from any thereof, (iii) waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any such suit, action, legal proceeding or claim in such courts and (iv) waives, to the fullest extent permitted by Law, the defense of an inconvenient forum to the maintenance of such suit, action, legal proceeding or claim in such courts. Each of the Parties hereto (A) agrees that a final judgment in any such suit, action, legal proceeding or claim shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law and (B) waives any objection to the recognition and enforcement by a court in other jurisdictions of any such final judgment. Each Party to this Assignment irrevocably consents to service of process inside or outside the territorial jurisdiction of the courts referred to in this Section 9 in the manner provided for notices in the Asset Purchase Agreement. Nothing in this Assignment will affect the right of any Party to this Assignment to serve process in any other manner permitted by Law.

[Signature Page Follows]

IN WITNESS WHEREOF, the Parties have caused this Assignment to be duly executed as of the day and year first above written.

ASSIGNOR:

MERRIMACK PHARMACEUTICALS, INC.


By: 
Name: Jeffrey A. Munsie
Title: General Counsel and Secretary

[SIGNATURE PAGE TO PATENT ASSIGNMENT]

Acknowledged and Accepted:

ASSIGNEE:

IPSEN BIOPHARM LTD.

By: 
Name: Jonathan Barnsley
Title: Chairman

[SIGNATURE PAGE TO PATENT ASSIGNMENT]

SCHEDULE A

ASSIGNED PATENTS

Country Code	Application status	Application Number	Filing Date	Patent Number	Issue Date	Application Title
AU	Granted	2013202947	8-Apr-13	2013202947	15-Sep-16	Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
AU	Published	2013274287	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
BR	Pending	BR1120140310882	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
CA	Published	2875824	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
CN	Published	2.0138E+12	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
EP	Published	13731230.2	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
HK	Published	15110395.3	22-Oct-15			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
IL	Published	235937	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
IN	Pending	11099/DELNP/2014	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
JP	Published	2015-517405	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
KR	Pending	10-2015-7000450	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
MX	Pending	MX/a/2014/015391	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
NZ	Pending	702469	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
RU	Published	2015100529	13-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan

Country Code	Application status	Application Number	Filing Date	Patent Number	Issue Date	Application Title
TW	Published	102120630	11-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
US	Expired	61/659,211	13-Jun-12			Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US	Expired	61/784,382	14-Mar-13			Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
US	Granted	14/406,776	10-Dec-14	9,452,162	27-Sep-16	Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
US	Granted	14/812,950	29-Jul-15	9,339,497	17-May-16	Track 1 - Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
US	Granted	14/844,500	3-Sep-15	9,364,473	14-Jun-16	Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan Methods For Treating Pancreatic Cancer
US	Granted	14/851,111	11-Sep-15	9,492,442	15-Nov-16	Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
US	Pending	15/341,377	2-Nov-16			Methods for Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
US	Abandoned	15/059,640	3-Mar-16			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
US	Published	15/241,128	19-Aug-16			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
US	Pending	15/341,619	2-Nov-16			Methods For Treating Pancreatic Cancer Using Combination Therapies
WO	Abandoned	PCT/US2013/044961	10-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
WO	Nat'l Phase	PCT/US2013/045495	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
ZA	Pending	2014/08804	12-Jun-13			Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
US	Expired	62/089,685	9-Dec-14			Treatment of Breast Cancer with Liposomal Irinotecan
US	Expired	62/265,409	9-Dec-15			Treatment of Breast Cancer with Liposomal Irinotecan

Country Code	Application status	Application Number	Filing Date	Patent Number	Issue Date	Application Title
US	Published	14/964,571	9-Dec-15			Treatment of Breast Cancer with Liposomal Irinotecan
US	Pending	15/375,039	9-Dec-16			Treatment of Breast Cancer with Liposomal Irinotecan
WO	Published	PCT/US2015/064491	8-Dec-15			Treatment of Breast Cancer with Liposomal Irinotecan
TW	Pending	105111702	14-Apr-16			Methods for Improving the Pharmacokinetics and Therapeutic Index of Sustained Release Drug Therapies ["DOUBLIRI"]
US	Expired	62/147,389	14-Apr-15			Methods for Improving the Pharmacokinetics and Therapeutic Index of Sustained Release Drug Therapies ["DOUBLIRI"]
WO	Expired	PCT/US2016/027515	14-Apr-16			COMPOSITIONS FOR IMPROVING THE PHARMACOKINETICS AND THERAPEUTIC INDEX OF CANCER TREATMENT
TW	Expired	105126680	19-Aug-16			Combination Therapy for Cancer Treatment
US	Expired	62/207,709	20-Aug-15			Combination Therapy for Cancer Treatment (PARPi, veliparib)
US	Pending	62/207,760	20-Aug-15			Combination Therapy for Cancer Treatment
US	Pending	62/269,756	18-Dec-15			Combination Therapy for Cancer Treatment
US	Pending	62/269,511	18-Dec-15			Combination Therapy for Cancer Treatment
US	Pending	62/323,422	15-Apr-16			Combination Therapy for Cancer Treatment
US	Pending	15/337,274	28-Oct-16			Combination Therapy for Cancer Treatment
WO	Expired	PCT/US2016/047827	19-Aug-16			Combination Therapy for Cancer Treatment
WO	Expired	PCT/US2016/047814	19-Aug-16			Combination Therapy for Cancer Treatment
TW	Pending	105126833	19-Aug-16			Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin

Country Code	Application status	Application Number	Filing Date	Patent Number	Issue Date	Application Title
US	Expired	62/208,209	21-Aug-15			Methods of Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
US	Expired	62/216,736	10-Sep-15			Methods of Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
US	Pending	62/273,244	30-Dec-15			Methods of Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
US	Pending	62/281,473	21-Jan-16			Methods of Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
US	Pending	62/302,341	2-Mar-16			Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
US	Pending	62/323,245	15-Apr-16			Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
US	Pending	62/343,313	31-May-16			Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
US	Pending	15/241,106	19-Aug-16			Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
WO	Pending	PCT/US2016/047727	19-Aug-16			Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
TW	Pending	105126832	19-Aug-16			Treatment of Pancreatic Cancer with Liposomal Irinotecan
US	Expired	62/207,435	20-Aug-15			Treatment of Pancreatic Adenocarcinoma with Liposomal Irinotecan
US	Expired	62/242,796	16-Oct-15			Treatment of Pancreatic Adenocarcinoma with Liposomal Irinotecan
US	Expired	62/243,935	20-Oct-15			Treatment of Pancreatic Adenocarcinoma with Liposomal Irinotecan
US	Expired	62/244,926	22-Oct-15			Treatment of Pancreatic Adenocarcinoma with Liposomal Irinotecan
US	Pending	62/278,751	14-Jan-16			Treatment of Pancreatic Cancer with Liposomal Irinotecan
US	Pending	62/281,458	21-Jan-16			Treatment of Pancreatic Cancer with Liposomal Irinotecan

Country Code	Application status	Application Number	Filing Date	Patent Number	Issue Date	Application Title
US	Pending	62/328,830	28-Apr-16			Treatment of Pancreatic Cancer with Liposomal Irinotecan
US	Pending	62/341,223	25-May-16			Treatment of Pancreatic Cancer with Liposomal Irinotecan
US	Pending	62/355,640	28-Jun-16			Treatment of Pancreatic Cancer with Liposomal Irinotecan
US	Expired	62/242,835	16-Oct-15			Liposomes with Improved Stability
US	Expired	62/242,873	16-Oct-15			Liposomes with Improved Stability
US	Expired	62/244,061	20-Oct-15			Irinotecan Liposomes with Improved Stability
US	Expired	62/244,082	20-Oct-15			Liposomes with Improved Stability
US	Pending	15/331,648	21-Oct-16			Liposomal Irinotecan Preparations
US	Pending	15/331,393	21-Oct-16			Liposomal Irinotecan Compositions
US	Pending	15/331,318	21-Oct-16			Liposomal Irinotecan Preparations
WO	Pending	PCT/US2016/057247	15-Oct-16			Stabilizing Camptothecin Pharmaceutical Compositions
TW	Pending	105133469	17-Oct-16			Liposomes with Improved Stability Filed as: Stabilizing Camptothecin Pharmaceutical Compositions
US	Pending	62/308,924	16-Mar-16			PARP Inhibitor and Irinotecan Liposome Combination Therapy for Cancer Treatment
US	Pending	62/338,324	18-May-16			Mechanism Based Population Pharmacokinetics of Liposomal Irinotecan
US	Pending	62/433,687	13-Dec-16			Population Pharmacokinetics of Liposomal Irinotecan
US	Pending	62/337,961	18-May-16			Treating Small Cell Lung Cancer with Nanoliposomal Irinotecan

Country Code	Application status	Application Number	Filing Date	Patent Number	Issue Date	Application Title
US	Pending	62/345,178	3-Jun-16			Treating Small Cell Lung Cancer with Nanoliposomal Irinotecan
US	Pending	62/362,735	15-Jul-16			Treating Small Cell Lung Cancer with Nanoliposomal Irinotecan
US	Pending	62/370,449	3-Aug-16			Treating Small Cell Lung Cancer with Nanoliposomal Irinotecan
US	Pending	62/394,870	15-Sep-16			Treating Small Cell Lung Cancer with Nanoliposomal Irinotecan
US	Pending	62/414,050	28-Oct-16			Treating Small Cell Lung Cancer with Nanoliposomal Irinotecan
US	Pending	62/415,821	1-Nov-16			Treating Small Cell Lung Cancer with Nanoliposomal Irinotecan
US	Pending	62/422,807	16-Nov-16			Treating Small Cell Lung Cancer with Nanoliposomal Irinotecan
US	Pending	62/433,925	14-Dec-16			Treating Small Cell Lung Cancer with Nanoliposomal Irinotecan
US	Pending	62/351,193	16-Jun-16			Treatment of Triple Negative Breast Cancer with Liposomal Irinotecan
US	Pending	62/430,470	6-Dec-16			Treatment of Breast Cancer with Liposomal Irinotecan
AU	Granted	2005240131	2-May-05	2005240131	16-Jun-11	Liposomes Useful for Drug Delivery
AU	Granted	2011202665	2-May-05	2011202665	5-Sep-13	Liposomes Useful for Drug Delivery
AU	Granted	2013207554	2-May-05	2013207554	8-Sep-16	Liposomes Useful for Drug Delivery
AU	Pending	2016203354	2-May-05			Liposomes Useful for Drug Delivery
CA	Granted	2566007	2-May-05	2566007	24-Sep-13	Liposomes Useful for Drug Delivery
CA	Granted	2821167	2-May-05	2821167	28-Jun-16	Liposomes Useful for Drug Delivery

Country Code	Application status	Application Number	Filing Date	Patent Number	Issue Date	Application Title
CN	Granted	200580022391.6	2-May-05	ZL200580022391.6	19-Feb-14	Liposomes Useful for Drug Delivery
CN	Published	201410025888.4	2-May-05			Liposomes Useful for Drug Delivery
EP	Granted	5745505.7	2-May-05	1746976	11-Jan-17	Liposomes Useful for Drug Delivery
HK	Published	7105202.6	16-May-07			Liposomes Useful for Drug Delivery
HK	Pending	15100533.7	15-Jan-15			Liposomes Useful for Drug Delivery
ID	Abandoned	W-00200603111	2-May-05			Liposomes Useful for Drug Delivery
IN	Pending	7275/DELNP/2006	2-May-05			Liposomes Useful for Drug Delivery
IN	Pending	7908/DELNP/2012	2-May-05			Liposomes Useful for Drug Delivery
JP	Granted	2007-511506	2-May-05	4971142	13-Apr-12	Liposomes Useful for Drug Delivery
JP	Granted	2011-266612	2-May-05	5502842	20-Mar-14	Liposomes Useful for Drug Delivery
JP	Granted	2013-241469	2-May-05	5665950	19-Dec-14	Liposomes Useful for Drug Delivery
KR	Granted	10-2006-7025074	2-May-05	1223366	10-Jan-13	Liposomes Useful for Drug Delivery
KR	Granted	10-2012-7017425	2-May-05	1376895	14-Mar-14	Liposomes Useful for Drug Delivery
KR	Granted	10-2013-7004524	2-May-05	10-1462819	11-Nov-14	Liposomes Useful for Drug Delivery
KR	Granted	10-2013-7030020	2-May-05	10-1462825	11-Nov-14	Liposomes Useful for Drug Delivery
NO	Pending	20065532	2-May-05			Liposomes Useful for Drug Delivery

Country Code	Application status	Application Number	Filing Date	Patent Number	Issue Date	Application Title
PH	Abandoned	1-2006-502175	2-May-05			Liposomes Useful for Drug Delivery
RU	Granted	2006142766	2-May-05	2424792	27-Jun-11	Liposomes Useful for Drug Delivery
RU	Granted	2011112461	2-May-05	2574926	1/15/2016	Liposomes Useful for Drug Delivery
RU	Pending	2015155368	2-May-05			Liposomes Useful for Drug Delivery
SG	Abandoned	200607609-5	2-May-05			Liposomes Useful for Drug Delivery
SG	Granted	201205085-2	2-May-05	196102	18-Mar-15	Liposomes Useful for Drug Delivery
TW	Granted	94114317	3-May-05	1359029	1-Mar-12	Liposomes Useful for Drug Delivery
UA	Granted	A200612696	2-May-05	86063	25-Mar-09	Liposomes Useful for Drug Delivery
US	Expired	60/567,921	3-May-04			Liposomes Useful for Drug Delivery
US	Granted	11/121,294	2-May-05	8,147,867	3-Apr-12	Liposomes Useful for Drug Delivery
US	Granted	11/601,451	17-Nov-06	8,658,203	25-Feb-14	Liposomes Useful for Drug Delivery to the Brain
US	Granted	13/416,204	9-Mar-12	8,329,213	11-Dec-12	Liposomes Useful for Drug Delivery
US	Granted	13/654,373	17-Oct-12	8,703,181	22-Apr-14	Liposomes Useful for Drug Delivery
US	Abandoned	14/151,632	9-Jan-14			Liposomes Useful for Drug Delivery to the Brain
US	Granted	14/175,365	7-Feb-14	8,992,970	31-Mar-15	Liposomes Useful for Drug Delivery
US	Published	14/632,422	26-Feb-15			Liposomes Useful for Drug Delivery

Country Code	Application status	Application Number	Filing Date	Patent Number	Issue Date	Application Title
US	Published	15/227,561	3-Aug-16			Liposomes Useful for Drug Delivery
US	Published	14/964,239	9-Dec-15			Liposomes Useful for Drug Delivery
US	Allowed	14/965,140	10-Dec-15			Liposomes Useful for Drug Delivery
US	Published	14/879,302	9-Oct-15			Liposomes Useful for Drug Delivery
US	Abandoned	14/879,358	9-Oct-15			Liposomes Useful for Drug Delivery
US	Published	15/227,631	3-Aug-16			Liposomes Useful for Drug Delivery
US	Published	14/966,458	11-Dec-15			Liposomes Useful for Drug Delivery
US	Published	14/979,666	28-Dec-15			Liposomes Useful for Drug Delivery
US	Pending	15/213,127	18-Jul-16			Liposomes Useful for Drug Delivery to the Brain
US	Pending	15/296,536	18-Oct-16			Liposomes Useful for Drug Delivery to the Brain
US	Pending	15/363,761	29-Nov-16			Liposomes Useful for Drug Delivery
US	Pending	15/363,923	29-Nov-16			Liposomes Useful for Drug Delivery
US	Pending	15/363,978	29-Nov-16			Liposomes Useful for Drug Delivery
US	Pending	15/364,021	29-Nov-16			Liposomes Useful for Drug Delivery
VN	Abandoned	1-2006-01983	2-May-05			Liposomes Useful For Drug Delivery And Method For Preparation Thereof
WO	Nat'l Phase	PCT/US2005/015349	2-May-05			Liposomes Useful for Drug Delivery

Country Code	Application status	Application Number	Filing Date	Patent Number	Issue Date	Application Title
US	Pending	62/416,317	2-Nov-16			Methods for Treating Gastric Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
US	Pending	29/581,798	21-Oct-16			CONTAINER - Onivyde Box and Vial with Solution